Obesity: Pathogenesis and emerging targets for drug development

Abstract

Obesity leads to premature death and impairs quality of life. In general, weight loss is responsible and reduced the risk of cardiovascular disease that is associated with obesity. One of the recognized and well establishment treatment option for weight loss i.e. pharmacotherapy where cardiovascular safety issues with some previous weight loss drugs raise concerns for newly approved pharmacotherapies. Previously, number of anti-obesity drugs that are already withdrawn from the market because of adverse side effects. In the present study, our group focused only on antiobesity drugs that are currently under investigation and also understand its pathogenesis.  Although lot of anti-obesity drugs are in the pipeline, the process for getting such type of drugs to be marketed has recently proven so difficult.